Agios Pharm Valuation
| AGIO Stock | USD 28.04 0.03 0.11% |
At this time, the firm appears to be fairly valued. Agios Pharm shows a prevailing Real Value of $28.84 per share. The current price of the firm is $28.04. Our model approximates the value of Agios Pharm from analyzing the firm fundamentals such as Operating Margin of (9.07) %, shares outstanding of 58.31 M, and Return On Equity of -0.28 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Agios Pharm's valuation include:
Price Book 1.2581 | Enterprise Value | Enterprise Value Ebitda (2.33) | Price Sales 36.0759 | Forward PE 2.4655 |
Fairly Valued
Today
Please note that Agios Pharm's price fluctuation is somewhat reliable at this time. Calculation of the real value of Agios Pharm is based on 3 months time horizon. Increasing Agios Pharm's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Agios Pharm is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Agios Stock. However, Agios Pharm's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 28.04 | Real 28.84 | Target 36.63 | Hype 27.99 |
The intrinsic value of Agios Pharm's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Agios Pharm's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Agios Pharm helps investors to forecast how Agios stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Agios Pharm more accurately as focusing exclusively on Agios Pharm's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Agios Pharm's intrinsic value based on its ongoing forecasts of Agios Pharm's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Agios Pharm's closest peers.
Agios Pharm Cash |
|
Agios Pharm Total Value Analysis
Agios Pharm is presently forecasted to have valuation of 707.53 M with market capitalization of 1.62 B, debt of 56.99 M, and cash on hands of 819.31 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Agios Pharm fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
707.53 M | 1.62 B | 56.99 M | 819.31 M |
Agios Pharm Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.26. Some equities with similar Price to Book (P/B) outperform the market in the long run. Agios Pharm recorded a loss per share of 7.01. The entity had not issued any dividends in recent years. Agios Pharm is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Agios Pharm Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Agios Pharm has an asset utilization ratio of 2.19 percent. This suggests that the Company is making $0.0219 for each dollar of assets. An increasing asset utilization means that Agios Pharm is more efficient with each dollar of assets it utilizes for everyday operations.Agios Pharm Profitability Analysis
Taking into consideration Agios Pharm's profitability measurements, Agios Pharm may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Agios Pharm's ability to earn profits and add value for shareholders.Net Income | First Reported 2011-12-31 | Previous Quarter -112 M | Current Value -103.4 M | Quarterly Volatility 140.6 M |
For Agios Pharm profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Agios Pharm to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Agios Pharm utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Agios Pharm's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Agios Pharm over time as well as its relative position and ranking within its peers.
Agios Pharm Earnings per Share Projection vs Actual
The next projected EPS of Agios Pharm is estimated to be -1.8208 with future projections ranging from a low of -2.03 to a high of -1.6956. Agios Pharm's most recent 12-month trailing earnings per share (EPS TTM) is at -7.01. Please be aware that the consensus of earnings estimates for Agios Pharm is based on EPS before non-recurring items and includes expenses related to employee stock options.Agios Pharm Earnings Estimation Breakdown
The calculation of Agios Pharm's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Agios Pharm is estimated to be -1.8208 with the future projection ranging from a low of -2.03 to a high of -1.6956. Please be aware that this consensus of annual earnings estimates for Agios Pharm is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-2.03 Lowest | Expected EPS | -1.7 Highest |
Agios Pharm Earnings Projection Consensus
Suppose the current estimates of Agios Pharm's value are higher than the current market price of the Agios Pharm stock. In this case, investors may conclude that Agios Pharm is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Agios Pharm's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 10 | 83.03% | 0.0 | -1.8208 | -7.01 |
Agios Pharm Ownership Allocation
The majority of Agios Pharm outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Agios Pharm to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Agios Pharm. Please pay attention to any change in the institutional holdings of Agios Pharm as this could imply that something significant has changed or is about to change at the company. On January 13, 2026, Representative Gilbert Cisneros of US Congress acquired under $15k worth of Agios Pharm's common stock.Agios Pharm Profitability Analysis
The company reported the previous year's revenue of 36.5 M. Net Income was 673.73 M with loss before overhead, payroll, taxes, and interest of (295.22 M).About Agios Pharm Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Agios Pharm. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Agios Pharm based exclusively on its fundamental and basic technical indicators. By analyzing Agios Pharm's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Agios Pharm's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Agios Pharm. We calculate exposure to Agios Pharm's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Agios Pharm's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 29.1 M | 28.7 M | |
| Pretax Profit Margin | (7.66) | (7.28) | |
| Operating Profit Margin | (8.74) | (9.18) | |
| Net Loss | (7.64) | (7.26) | |
| Gross Profit Margin | 0.88 | 0.93 |
Agios Pharm Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 57.9 M | |
| Forward Price Earnings | 2.4655 |
Agios Pharm Current Valuation Indicators
Agios Pharm's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Agios Pharm's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Agios Pharm, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Agios Pharm's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Agios Pharm's worth.When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Will Biotechnology sector continue expanding? Could Agios diversify its offerings? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Agios Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (7.01) | Revenue Per Share | Quarterly Revenue Growth 0.437 | Return On Assets | Return On Equity |
Agios Pharm's market price often diverges from its book value, the accounting figure shown on Agios's balance sheet. Smart investors calculate Agios Pharm's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Agios Pharm's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Agios Pharm's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Agios Pharm represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.